CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

CVRx (NASDAQ: CVRX), a commercial-stage medical device company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to deliver a presentation on Wednesday, January 15, 2025, at 2:15 PM Pacific Time. Interested parties can access a live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.

News Market Reaction – CVRX

+3.20%

+3.20% Session move

In the trading session that priced this news, CVRX gained 3.20%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.

About CVRx, Inc.

CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:

Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com

FAQ

When is CVRx presenting at the 2025 J.P. Morgan Healthcare Conference?

CVRx is scheduled to present on Wednesday, January 15, 2025, at 2:15 PM Pacific Time.

How can investors watch CVRx's J.P. Morgan Healthcare Conference presentation?

Investors can watch the live audio webcast of CVRx's presentation through the investor relations page of the company's website at ir.cvrx.com.

Which healthcare conference will CVRx be presenting at in January 2025?

CVRx will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.

Will CVRx's presentation at the J.P. Morgan Healthcare Conference be available online?

Yes, CVRx's presentation will be available via live audio webcast on their investor relations website.